Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

被引:138
作者
Birkeland, Kare, I [1 ,2 ]
Bodegard, Johan [3 ]
Eriksson, Jan W. [4 ]
Norhammar, Anna [5 ,6 ,7 ]
Haller, Hermann [8 ]
Linssen, Gerard C. M. [9 ]
Banerjee, Amitava [10 ,11 ]
Thuresson, Marcus [12 ]
Okami, Suguru [13 ]
Garal-Pantaler, Elena [14 ]
Overbeek, Jetty [15 ]
Mamza, Jil Billy [16 ]
Zhang, Ruiqi [16 ]
Yajima, Toshitaka [13 ]
Komuro, Issei [17 ]
Kadowaki, Takashi [18 ,19 ]
机构
[1] Oslo Univ Hosp, Oslo, Norway
[2] Univ Oslo, Oslo, Norway
[3] AstraZeneca, Oslo, Norway
[4] Uppsala Univ, Dept Med Sci Clin Diabet & Metab, Uppsala, Sweden
[5] Dept Med, Cardiol Unit, Solna, Sweden
[6] Karolinska Inst, Stockholm, Sweden
[7] St Gorans Univ Hosp, Stockholm, Sweden
[8] Hannover Med Sch, Div Nephrol, Hannover, Germany
[9] Hosp Grp Twente, Dept Cardiol, Hengelo, Netherlands
[10] UCL, Inst Hlth Informat, London, England
[11] Univ Coll London Hosp, Dept Cardiol, London, England
[12] Statisticon AB, Uppsala, Sweden
[13] AstraZeneca, Osaka, Japan
[14] Team Gesundheit GmbH, Essen, Germany
[15] PHARMO Inst Drug Outcomes Res CRS, Utrecht, Netherlands
[16] AstraZeneca, Luton, Beds, England
[17] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan
[18] Univ Tokyo, Grad Sch Med, Dept Prevent Diabet & Lifestyle Related Dis, Tokyo, Japan
[19] Teikyo Univ, Mizonokuchi Hosp, Dept Metab & Nutr, Kawasaki, Kanagawa, Japan
关键词
diabetic nephropathy; heart failure; macrovascular disease; observational study; type; 2; diabetes; SGLT2; inhibitor; CARDIOVASCULAR OUTCOMES; PATHOPHYSIOLOGY; PREVALENCE; MELLITUS; ATHEROSCLEROSIS; EMPAGLIFLOZIN; ABNORMALITIES; EPIDEMIOLOGY; DIAGNOSIS; IMPACT;
D O I
10.1111/dom.14074
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD-free status. Results Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD-free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all-cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75-2.33) and HR 2.05 (95% CI 1.82-2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all-cause mortality risk: HRs 3.91 (95% CI 3.02-5.07) and 3.14 (95% CI 2.90-3.40), respectively. Conclusion In a large multinational study of >750 000 CVRD-free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.
引用
收藏
页码:1607 / 1618
页数:12
相关论文
共 58 条
[1]   Kidney Disease and Increased Mortality Risk in Type 2 Diabetes [J].
Afkarian, Maryam ;
Sachs, Michael C. ;
Kestenbaum, Bryan ;
Hirsch, Irl B. ;
Tuttle, Katherine R. ;
Hinnmelfarb, Jonathan ;
de Boer, Ian H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02) :302-308
[2]  
[Anonymous], 2017, GLOB PICT DIAB FACT
[3]   The Population Burden of Heart Failure Attributable to Modifiable Risk Factors The ARIC (Atherosclerosis Risk in Communities) Study [J].
Avery, Christy L. ;
Loehr, Laura R. ;
Baggett, Christopher ;
Chang, Patricia P. ;
Kucharska-Newton, Anna M. ;
Matsushita, Kunihiro ;
Rosamond, Wayne D. ;
Heiss, Gerardo .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) :1640-1646
[4]   Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].
Basta, G ;
Schmidt, AM ;
De Caterina, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :582-592
[5]   Heart failure prevalence, incidence, and mortality in the elderly with diabetes [J].
Bertoni, AG ;
Hundley, WG ;
Massing, MW ;
Bonds, DE ;
Burke, GL ;
Goff, DC .
DIABETES CARE, 2004, 27 (03) :699-703
[6]   Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].
Bikbov, Boris ;
Purcell, Carrie ;
Levey, Andrew S. ;
Smith, Mari ;
Abdoli, Amir ;
Abebe, Molla ;
Adebayo, Oladimeji M. ;
Afarideh, Mohsen ;
Agarwal, Sanjay Kumar ;
Agudelo-Botero, Marcela ;
Ahmadian, Elham ;
Al-Aly, Ziyad ;
Alipour, Vahid ;
Almasi-Hashiani, Amir ;
Al-Raddadi, Rajaa M. ;
Alvis-Guzman, Nelson ;
Amini, Saeed ;
Andrei, Tudorel ;
Andrei, Catalina Liliana ;
Andualem, Zewudu ;
Anjomshoa, Mina ;
Arabloo, Jalal ;
Ashagre, Alebachew Fasil ;
Asmelash, Daniel ;
Ataro, Zerihun ;
Atout, Maha Moh'd Wahbi ;
Ayanore, Martin Amogre ;
Badawi, Alaa ;
Bakhtiari, Ahad ;
Ballew, Shoshana H. ;
Balouchi, Abbas ;
Banach, Maciej ;
Barquera, Simon ;
Basu, Sanjay ;
Bayih, Mulat Tirfie ;
Bedi, Neeraj ;
Bello, Aminu K. ;
Bensenor, Isabela M. ;
Bijani, Ali ;
Boloor, Archith ;
Borzi, Antonio M. ;
Camera, Luis Alberto ;
Carrero, Juan J. ;
Carvalho, Felix ;
Castro, Franz ;
Catala-Lopez, Ferran ;
Chang, Alex R. ;
Chin, Ken Lee ;
Chung, Sheng-Chia ;
Cirillo, Massimo .
LANCET, 2020, 395 (10225) :709-733
[7]   How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study [J].
Birkeland, Kare I. ;
Bodegard, Johan ;
Norhammar, Anna ;
Kuiper, Josephina G. ;
Georgiado, Elena ;
Beekman-Hendriks, Wendy L. ;
Thuresson, Marcus ;
Pignot, Marc ;
Herings, Ron M. C. ;
Kooy, Adriaan .
DIABETES OBESITY & METABOLISM, 2019, 21 (04) :968-974
[8]   Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis [J].
Birkeland, Kare I. ;
Jorgensen, Marit E. ;
Carstensen, Bendix ;
Persson, Frederik ;
Gulseth, Hanne L. ;
Thuresson, Marcus ;
Fenici, Peter ;
Nathanson, David ;
Nystrom, Thomas ;
Eriksson, Jan W. ;
Bodegard, Johan ;
Norhammar, Anna .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09) :709-717
[9]   Diabetes, heart failure, and renal dysfunction: The vicious circles [J].
Braunwald, Eugene .
PROGRESS IN CARDIOVASCULAR DISEASES, 2019, 62 (04) :298-302
[10]   CKD Prevalence Varies across the European General Population [J].
Bruck, Katharina ;
Stel, Vianda S. ;
Gambaro, Giovanni ;
HaIlan, Stein ;
Volzke, Henry ;
Arnlov, Johan ;
Kastarinen, Mika ;
Guessous, Idris ;
Vinhas, Jose ;
Stengel, Benedicte ;
Brenner, Hermann ;
Chudek, Jerzy ;
Romundstad, Solfrid ;
Tomson, Charles ;
Otero Gonzalez, Alfonso ;
Bello, Aminu K. ;
Ferrieres, Jean ;
Palmieri, Luigi ;
Browne, Gemma ;
Capuano, Vincenzo ;
Van Biesen, Wim ;
Zoccali, Carmine ;
Gansevoort, Ron ;
Navis, Gerjan ;
Rothenbacher, Dietrich ;
Ferraro, Pietro Manuel ;
Nitsch, Dorothea ;
Wanner, Christoph ;
Jager, Kitty J. ;
Consortium, European C. K. D. Burden .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (07) :2135-2147